Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;100(5):656-673.
doi: 10.1111/cbdd.14130. Epub 2022 Aug 19.

Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy

Alaa M Ali  1 , Samar S Tawfik  1 , Amany S Mostafa  1 , Mohammed A M Massoud  1
Affiliations
Review

Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy

Alaa M Ali et al. Chem Biol Drug Des. 2022 Nov.

Abstract

Targeted therapy has emerged to be the cornerstone of advanced cancer treatment, allowing for more selectivity and avoiding the common drug toxicity and resistance. Identification of potential targets having vital role in growth and survival of cancer cells got much easier with the aid of the recent advances in high throughput screening approaches. Various protein kinases came into focus as valuable targets in cancer therapy. Meanwhile, benzimidazole-based scaffolds have gained significant attention as promising protein kinase inhibitors with high potency and varied selectivity. Great diversity of these scaffolds has inspired the medicinal chemists to inspect the effect of structural changes upon inhibitory activity on the molecular level through modeling studies. The present review gathers all the considerable attempts to develop benzimidazole-based compounds; designed as protein kinase inhibitors with anticancer activity since 2015; that target aurora kinase, CDK, CK2, EGFR, FGFR, and VEGFR-2; to allow further development and progression regarding benzimidazoles.

Keywords: benzimidazole; cancer; inhibitors; protein kinase; targeted therapy.

PubMed Disclaimer

References

REFERENCES

    1. Abd El-All, A. S., Magd-El-Din, A. A., Ragab, F. A., ElHefnawi, M., Abdalla, M. M., Galal, S. A., & El-Rashedy, A. A. (2015). New benzimidazoles and their antitumor effects with Aurora A kinase and KSP inhibitory activities. Archiv der Pharmazie, 348(7), 475-486. https://doi.org/10.1002/ardp.201400441
    1. Abdel-Mohsen, H. T., Abdullaziz, M. A., Kerdawy, A. M. E., Ragab, F. A. F., Flanagan, K. J., Mahmoud, A. E. E., Ali, M. M., Diwani, H. I. E., & Senge, M. O. (2020). Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: Rational design, synthesis and biological evaluation of 1,2-disubstituted benzimidazoles. Molecules, 25(4), 770. https://doi.org/10.3390/molecules25040770
    1. Abdullaziz, M. A., Abdel-Mohsen, H. T., El Kerdawy, A. M., Ragab, F. A. F., Ali, M. M., Abu-Bakr, S. M., Girgis, A. S., & El Diwani, H. I. (2017). Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. European Journal of Medicinal Chemistry, 136, 315-329. https://doi.org/10.1016/j.ejmech.2017.04.068
    1. Akhtar, M. J., Khan, A. A., Ali, Z., Dewangan, R. P., Rafi, M., Hassan, M. Q., Akhtar, M. S., Siddiqui, A. A., Partap, S., Pasha, S., & Yar, M. S. (2018). Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorganic Chemistry, 78, 158-169. https://doi.org/10.1016/j.bioorg.2018.03.002
    1. Akhtar, M. J., Siddiqui, A. A., Khan, A. A., Ali, Z., Dewangan, R. P., Pasha, S., & Yar, M. S. (2017). Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors. European Journal of Medicinal Chemistry, 126, 853-869. https://doi.org/10.1016/j.ejmech.2016.12.014

MeSH terms